A Study of APS03118 in Advanced Solid Tumors Harboring RET Mutations or Fusions
Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety,
tolerability, pharmacokinetics (PK) and preliminary antineoplastic activity of APS03118
administered orally in participants with RET-altered solid tumors.